Malignancies in systemic lupus erythematosus: A 2015 update

Current Opinion in Rheumatology

Volumn 27, Issue 5, 2015, Pages 454-460

  Goobie, Gillian C ^a   Bernatsky, Sasha ^b   Ramsey Goldman, Rosalind ^c   Clarke, Ann E ^a  

^a UNIVERSITY OF CALGARY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Breast cancer; Lymphoma; Malignancy; Systemic lupus erythematosus

Indexed keywords

BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL PRACTICE; HEMATOLOGIC MALIGNANCY; HEPATOBILIARY SYSTEM CANCER; HUMAN; LIVER CANCER; LUNG CANCER; NEOPLASM; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; THYROID CANCER; UTERINE CERVIX CANCER; VAGINA CANCER; VIRUS INFECTION; VULVA CARCINOMA; COMPLICATION; DISEASE PREDISPOSITION; NEOPLASMS; PATHOPHYSIOLOGY;

DISEASE SUSCEPTIBILITY; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; NEOPLASMS;

EID: 84942565710     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000202     Document Type: Review

References (58)

1. Bernatsky S, Ramsay-Goldman R, Labrecque J, et al. Cancer risk in systemic lupus: an updated international multicentre cohort study. J Autoimmun 2013; 42:130-135.
2. Chen YJ, Chang YT, Wang CB, et al. Malignancy in systemic lupus erythematosus: a nation-wide cohort study in Taiwan. Am J of Medicine 2010; 123:1150-1156.
3. Dey D, Kenu E, Isenberg DA. Cancer complicating systemic lupus erythematosus: a dichotomy emerging from a nested case-control study. Lupus 2013; 22:919-927.
4. Dreyer L, Faurschou M, Mogensen M, Jacobsen S. High incidence of potentially virus-induced malignancies in systemic lupus erythematosus: a long-term follow-up study in a Danish cohort. Arthritis Rheum 2011; 63:3032-3037.
5. Ni J, Qui LJ, Hu LF, et al. Lung, liver, prostate, bladder malignancies risk in systemic lupus erythematosus: a meta-Analysis. Lupus 2015; 23:284-292. A meta-Analysis including seven cohort studies published between 1997 and 2013 (total number of patients 63585). This analysis demonstrated an increased risk of cancer overall aswell as lung and liver cancer, but a decreased risk of prostate cancer.
6. Thomas G , Mancini J, Jourde-Ciche N, et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheum 2014; 66:2503-2511.
7. Yurkovic h M, Vostretsova K, Chen W, Aviña-Zubieta JA. Overall and causespecific mortality in patients with systemic lupus erythematosus: a metaanalysis of observational studies. Arthritis Care Res 2014; 66:608-616.
8. Lu M, Bernatsky S, Ramsey-Goldman R, et al. Nonlymphoma hematologic malignancies in systemic lupus erythematosus. Oncology 2013; 85:235-240.
9. Fallah M, Liu X, Ji J, et al. Autoimmune diseases associated with non-Hodgkin lymphoma: a nationwide cohort study. Ann Oncol 2014; 25:2025-2030. Using the Swedish Cancer Registry, this study assessed close to 1 million Swedish patients diagnosed with autoimmune diseases and found that NHL was elevated in a large number of autoimmune diseases, including a greatly increased in risk SLE.
10. Apor E, O'Brien J, Stephen M, Castillo JJ. Systemic lupus erythematosus is associated with increased inc idence of hematologic malignancies: a metaanalysis of prospective cohort studies. Leuk Res 2014; 38:1067-1071. This is a large meta-Analysis evaluating cohorts published between 1992 and 2013 (including approximately 68 000 patients wit h SLE) demonstrating increased incidences of all hematologic malignancies.
11. Bernatsky S, Ramsey-Goldman R, Joseph L, et al. Lymphoma risk in systemic lupus: effects of disease activity versus treatment. Ann R heum Dis 2014; 73:138-142. This is a case-cohort study nested within an international cohort that compared disease activity and medication exposure between patients with SLE with and without lymphoma. Disease activity did not differ and h igher cumulative steroid doses and cyclophosphamide exposure conferred an increased risk of lymphoma.
12. Draborg AH, Duus K, Houen G. Epstein-Barr virus in systemic autoimmune diseases. Clin Dev Immunol 2013; 2013:1-9.
13. Rasmussen NS, Draborg AH, Nielsen CT, et al. Antibodies to early EBV, CMV, and HHV6 antigens in systemic lupus patients. Scand J Rheumatol 2014; 44:143-149.
14. Hanlon P, Avenell A, Aucott L, Vickers MA. Systematic review and metaanalysis of the sero-epidemiological association between Epstein-Barr virus and systemic lupus erythematosus. Arthritis Res Ther 2014; 16:R3.
15. Bollard CM,Gottschalk S,Torrano S,et al. Sustained complete responses in patients with lymphoma receiving autologous cytotoxic T lymphocytes targeting Epstein-Barr virus latent membrane proteins. J Clin Onc 2014 32 798-808.
16. Capone G, Fasano C, Lucchese G, et al. EBV-Associated cancer and autoimmunity: searching for therapies. Vaccines 2015; 3:74-89. This is the firs t study to find an Epstein-Barr nuclear antigen peptide sequence that is not found in the human genome and it may serve as a sequence for future vaccine development. They suggest this type of vaccine may help to decrease EBV-Associated malignancy and auto immunity, including SLE.
17. Yao X, Huang J, Zhong H, et al. Targeting interleukin-6 in inflammatory autoimmune diseases and cancers. Pharmacol Therap 2014; 141:125-139.
18. Heinrich PC, Behrmann I, Haan S, et al. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 2003; 374:1-20.
19. Zhang L, Yang J, Qi an J, et al. Role of the microenvironment in mantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 2012; 120:3783-3792.
20. Miaer-Moore JS, Horton CG, Mathews SA, et al. Interleukin-6 deficiency corrects nephritis, lymphocyte abnormalities, and secondary Sjögren's syndrome features in lupus-prone Sle1.Yaa Mice. Arthritis Rheumatol 2014; 66:2521-2531. This study implicated interleukin-6 in the pathogenesis of SLE, B-cell proliferation and autoantibody production. Inhibition of interleukin-6 resulted in decreased autoantibodies, decreased proliferation and differentiation of T and B cells, and decreased lymphocytic infiltration of the kidneys, l ungs, and salivary glands.
21. Shirota Y, Yarboro C, Fischer R, et al. Impact of antiinterleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Di s 2013; 72:118-128.
22. Vincent FB, Morand EF, Schneider P, Mackay F. The BAFF/APRIL system in SLE pathogenesis. Nat Rev Rheumatol 2014; 10:365-373.
23. Z ollars E, Fang H, Bienkowska J, et al. Only BAFF mRNA, not BAFF protein level in blood, is associated with SLE activity over one year. Ann Rheum Dis 2015; 74:A74.
24. Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-731.
25. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011; 63:3918-3930.
26. Lyu MA, Pham LV, Sung B, et al. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma. Biochem Parmacol 2012; 84:451-458. This is the first study to show that inhibition of BAFF pathways may present a target for the treatment of aggressive forms of NHL, such as mantle cell lymphoma. This study targeted mantle cell lymphoma in mice with an rGek/BLyS (i.e. rGel/BAFF) fusion protein and fo und increased survival.
27. Löfström B, Backlin C, Pettersson T, et al. Expression of APRIL in diffuse large B cell lymphomas from patients with systemic lupus erythematosus and rheumatoid arthritis. J Rheumatol 2011; 38:1891-1897.
28. Hoffman FS, Kuhn PH, Laurent SA, et al. The immunoregulator soluble TACI is released by ADAM10 and reflects B cell activation in autoimmunity. J Immunol 2015; 194:5 42-552. This study found that sTACI levels were increased in sera of patients with SLE and were associated with increased disease activity.
29. Lascano V, Guadagnoli M, Schot JG, et al. Chronic lymphocytic leukemia d isease progression is accelerated by APRIL-TACI interaction in the TCL1 transgenic mouse model. Blood 2013; 122:3960-3963.
30. Kufer P, Raum T, Hoffmann P, et al. Binding molecules for BCMA and CD3. United States Amegen Research (Munich) 2014; 20140348837. May 1, 2015. http://www.freepatentsonline.com/y2014/0348837.html.
31. Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial). Ann Rheum Dis 2014; 0:1-10.
32. Guadagnoli M, Kimberley FC, Phan U, et al. Development and characterization of APRIL a ntagonistic monoclonal antibodies for treatment of B-cell lymphomas. Blood 2011; 117:6856-6865.
33. Hemminki K, Liu X, Ji J, et al. Effect of autoimmune diseases on risk and survival in histology-specific lung cancer. Eur Resp J 2012; 40:1489-1495.
34. Ekblom-Kullberg S, Kautiainen H, Alha P, et al. Smoking and the risk of systemic lupus erythematosus. Clin Rheumatol 2013; 32:1219-1222.
35. Kim NH, Kim SK, Kim DS, et al. Antiproliferative action of IL-6R-targeted antibody tocilizumab for nonsmall cell lung cancer cells. Oncol Lett 2015; 9:2283-2288.
36. Rossi JF, Lu Zy, Jourdan M, Klein B. Interleukin-6 as a therapeutic target. Clin Cancer Res 2015; 21:1248-1257.
37. Castro FA, Liu X, Forsti A, et al. Increased risk of hepatobiliary cancers after hospitalization for autoimmune disease. Clin Gastroenterol Hepatol 2014; 12:1038-1045. This is a large cohort study based on Swedish cancer registries that demonstrated a link between primary liver can c er and 14 different autoimmune diseases, including SLE. Also looked at the rates of gallbladder and extrahepatic bile duct cancers in autoimmune diseases, but did not find increased incidences in SLE.
38. Ahmed MM, Berney SM, Wolf RE, et al. Prevalence of active hepatitis C virus infection in patients with systemic lupus erythematosus. Am J Med Sci 2006; 331:252-325.
39. Bernatsky S, Ramsey-Goldman R, Foulkes W, et al. Breast, ovarian, and endometrial malignancies in systemic lupus erythematosus: a meta-Analysis. Br J Cancer 2011; 104:1478-1481.
40. Hansen JE, Chan G, Liu Y, et al. Targeting cancer with a lupus autoantibody. Sci Transl Med 2012; 4:142-157.
41. Tessier-Cloutier B, Clarke AE, Ramsey-Goldman R, et al. Breast cancer in systemic lupus erythematosus. Oncology 2013; 85:117-121.
42. Noble PW, Young MR, Bernatsky S, et al. A nucleolytic lupus autoantibody is toxic to BRCA2-deficient cancer cells. Sci Rep 2014; 5:1-4. This is a second major study (first is [40]) to demons trate that an anti-dsDNA antibody (anti5C6) results in decreased survival and increased susceptibility to treatment of BRCA2-deficient cancer cells.
43. Rai R, Chauhan SK, Singh VV, et al. Heat shock protein 27 and i ts regulatory molecules express differentially in SLE patients with distinct autoantibody profiles. Immunol Lett 2015; 164:25-32. This is the first study to demonstrate significantly decreased levels of HSP-27 in patients with SLE, a n d found these specifically in patients who were ENApositive. HSP-27 is characterized by its antiapoptotic properties, and thus decreased expression of this protein may result in increased apoptosis of malignant cell lines.
44. Grzegrzolka J,Kurnol K,Piotrow P,et al. Hsp27 expression in invasive ductal breast carcinoma Folia Histo Cytobio 2012 50 527-533
45. Straume O, Shimamura T, Lampa MJG, et al. Suppression of heat shock protein 27 induces long-term dormancy in human breast cancer. Proc Natl Acad Sci USA 2012; 109:8699-8704.
46. Dáz-Chá vez J, Fonseca-Sánches MA, Arechaga-Ocampo E, et al. Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS One 2013; 8:1-12.
47. Zard E, Arnaud L, Mathian A, et al. Increased risk of high grade cervical squamous cell intraepithelial lesions in systemic lupus erythematosus: a metaanalysis of the literature. Autoimmun Rev 2014; 13:730-7 35. This is a meta-Analysis of seven studies published between 2001 and 2012 looking at the rates of high-grade cervical squamous epithelial lesions in 416 patients with SLE that demonstrated increased risk of these lesions. They suggest this may be r elated to altered HPV clearance in SLE.
48. Lyrio LDC, Grassi MFR, Santana IU, et al. Prevalence of cervical human papillomavirus infection in women with systemic lupus erythematosus. Rheumatol Int 2013; 33:335-340.
49. Huang HB, Jiang SC, Han J, et al. A systematic review of the epidemiological literature on the risk of urological cancers in systemic lupus erythematosus. J Cancer Res Clin Oncol 2014; 14 0:1067-1073. This is a systematic review of 12 studies, including a total of 68 336 patients with SLE that assesses the risk of prostate, bladder, and kidney cancer. It reported decreased rates of prostate cancer and a trend toward increased bladde r cancer.
50. Liu X, Ji J, Forsti A, et al. Autoimmune diseases and subsequent urological cancer. J Urol 2013; 189:2262-2268.
51. Ischia J, Saad F, Gleave M. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr Opin Urol 2013; 23:194-200.
52. Foster CS, Dodson AR, Ambroisine L, et al. Hsp-27 expre ssion at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement. Br J Cancer 2009; 101:1137-1144.
53. Lamoureux F, Thomas C, Yin MJ, et al. Suppression of he at shock protein 27 using OGX-427 induces endoplasmic reticulum stress and potentiates heat shock protein 90 inhibitors to delay castrate-resistant prostate cancer. Eur Urol 2014; 66:145-155.
54. Zhang M, Li XM, Wang GS, et al. Thyroid cancer in systemic lupus erythematosus: a meta analysis. Int J Clin Exp Pathol 2014; 7:6270-6273. This is a meta-Analysis of seven cohorts published between 2003 and 2013 that demonstrated an i ncreased risk of thyroid cancer in 66 093 patients with SLE. This study suggested there may be a link between autoimmune thyroid disease and thyroid cancer in patients with SLE.
55. Antonelli A, Mosca M, Fallahi P, et al. Thyroid cancer in systemic lupus erythematosus: a case-control study. J Clin Endocrinol Metab 2010; 95:314-318.
56. Tessier-Cloutier B, Clarke AE, Pineau CA, et al. What investigations are n eeded to optimally monitor for malignancies in SLE? Lupus 2015; 0:1-7. This is a systematic review to identify original research on cancer screening recommendations specifically for patients with SLE. No such recommendations were found an d they recommended adherence to general population recommendations.
57. Dawar M, Harris T, McNeil S. National Advisory Committee on Immunization (NACI) update on human papillomavirus (HPV) vaccines. Canada Communicab le Disease Report 2012; 38:1-62.
58. Mok CC, Ho LY, Fong LS, To CH. Immunogenicity and safety of a quadrivalent human papillomavirus vaccine in patients with systemic lupus erythematosus: a case-con trol study. Ann Rheum Dis 2013; 72:659-664.